相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Identification of somatic JAK1 mutations in patients with acute myeloid leukemia
Zhifu Xiang et al.
BLOOD (2008)
Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice
Ralph Tiedt et al.
BLOOD (2008)
JAK2 stimulates homologous recombination and genetic instability: potential implication in the heterogeneity of myeloproliferative disorders
Isabelle Plo et al.
BLOOD (2008)
Somatic mutations and germline sequence variants in the expressed tyrosine kinase genes of patients with de novo acute myeloid leukemia
Michael H. Tomasson et al.
BLOOD (2008)
Selective inhibition of JAK2-Driven erythroid differentiation of polycythemia vera progenitors
Ifat Geron et al.
CANCER CELL (2008)
Expansion of Bcr-Abl-positive leukemic stem cells is dependent on hedgehog pathway activation
Christine Dierks et al.
CANCER CELL (2008)
Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera
Gerlinde Werning et al.
CANCER CELL (2008)
A BCR-JAK2 fusion gene as the result of a t(9;22)(p24;q11) in a patient with acute myeloid leukemia
Gabriella Cirmena et al.
CANCER GENETICS AND CYTOGENETICS (2008)
Somatic mutations of JAK1 and JAK3 in acute leukemias and solid cancers
Eun Goo Jeong et al.
CLINICAL CANCER RESEARCH (2008)
Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis
Srdan Verstovsek et al.
CLINICAL CANCER RESEARCH (2008)
Dasatinib therapy for systemic mastocytosis: four cases
Duncan Purtill et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2008)
The t(1;9)(p34;q34) and t(8;12)(p11;q15) fuse pre-mRNA processing proteins SFPQ (PSF) and CPSF6 to ABL and FGFR1
Claire Hidalgo-Curtis et al.
GENES CHROMOSOMES & CANCER (2008)
Novel SSBP2-JAK2 fusion gene resulting from a t(5;9)(q14.1;p24.1) in pre-B acute lymphocytic leukemia
Jennifer L. Poitras et al.
GENES CHROMOSOMES & CANCER (2008)
Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia
Elisabetta Flex et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2008)
Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome
Dani Bercovich et al.
LANCET (2008)
Comparison of mutated ABL1 and JAK2 as oncogenes and drug targets in myeloproliferative disorders
C. Walz et al.
LEUKEMIA (2008)
TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients
T. L. Lasho et al.
LEUKEMIA (2008)
Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival
A. Tefferi et al.
LEUKEMIA (2008)
JAK2 mutations other than V617F: A novel mutation and mini review
Axel Karow et al.
LEUKEMIA RESEARCH (2008)
The JAK kinases: Not just another kinase drug discovery target
Andrew F. Wilks
SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY (2008)
Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders
Elizabeth O. Hexner et al.
BLOOD (2008)
Host genetic variation contributes to phenotypic diversity in myeloproliferative disorders
Animesh Pardanani et al.
BLOOD (2008)
Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders
Daniela Pietra et al.
BLOOD (2008)
The history of myeloproliferative disorders: before and after Dameshek
A. Tefferi
LEUKEMIA (2008)
Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithms
A. Tefferi et al.
LEUKEMIA (2008)
Development of ET, primary myelofibrosis and PV in mice expressing JAK2 V617F
K. Shide et al.
LEUKEMIA (2008)
JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials
A. Pardanani
LEUKEMIA (2008)
Two novel JAK2 exon 12 mutations in JAK2V617F-negative polycythaemia vera patients
C. M. Butcher et al.
LEUKEMIA (2008)
Activity of imatinib in systemic mastocytosis with chronic basophilic leukemia and a PRKG2-PDGFRB fusion
Idoya Lahortiga et al.
HAEMATOLOGICA (2007)
JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis
Giovanni Barosi et al.
BLOOD (2007)
JAK2 exon 12 mutations in polycythemia vera or idiopathic erythrocytosis
Luz Martinez-Aviles et al.
HAEMATOLOGICA (2007)
The frequency of JAK2 exon 12 mutations in idiopathic erythrocytosis patients with low serum erythropoietin levels
Melanie J. Percy et al.
HAEMATOLOGICA (2007)
Evidence for MPL W515L/K mutations in hematopoietic stem cells in primitive myelofibrosis
Ronan Chaligne et al.
BLOOD (2007)
Prevalance of JAK2 V617F and exon 12 mutations in polycythaemia vera
Linda M. Scott et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
Part I: Mechanisms of resistance to imatinib in chronic myeloid leukaemia
Jane F. Apperley
LANCET ONCOLOGY (2007)
Demonstration of MPLW515K, but not JAK2V617F, in in vitro expanded CD4+ T lymphocytes
A. Pardanani et al.
LEUKEMIA (2007)
Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia
Thomas O'Hare et al.
BLOOD (2007)
A new JAK2 gene mutation in patients with polycythemia vera and splanchnic vein thrombosis
Donatella Colaizzo et al.
BLOOD (2007)
Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera
A. Pardanani et al.
LEUKEMIA (2007)
Prospective identification of high-risk polycythemia vera patients based on JAK2V617F allele burden
A. M. Vannucchi et al.
LEUKEMIA (2007)
Extending Jak2V617F and MplW515 mutation analysis to single hematopoietic colonies and B and T lymphocytes
Animesh Pardanani et al.
STEM CELLS (2007)
Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelotibrosis: recommendations from an ad hoc international expert panel
Ayalew Tefferi et al.
BLOOD (2007)
Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia
Alessandro M. Vannucchi et al.
BLOOD (2007)
Sensitivity of human cells bearing oncogenic mutant kit isoforms to the novel tyrosine kinase inhibitor INNO-406
Jingxuan Pan et al.
CANCER SCIENCE (2007)
TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations
A. Pardanani et al.
LEUKEMIA (2007)
The JAK2 617V>F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera
Sabrina Dupont et al.
BLOOD (2007)
JAK-STAT signaling: From interferons to cytokines
Christian Schindler et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Leukemic blasts in transfon-ned JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation
Alexandre Theocharides et al.
BLOOD (2007)
Studies of c-Mpl function distinguish the replication of hematopoietic stem cells from the expansion of differentiating clones
Janis L. Abkowitz et al.
BLOOD (2007)
Clinical correlates of JAK2V617F allele burden in essential thrombocythemia
Jaya Kittur et al.
CANCER (2007)
Anaemia characterises patients with myelofibrosis harbouring MplW515L/K mutation
Paola Guglielmelli et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
Novel activating JAK2 mutation in a patient with Down syndrome and B-cell precursor acute lymphoblastic leukemia
Sebastien Malinge et al.
BLOOD (2007)
The investigation of JAK2 mutation in Chinese myeloproliferative diseases-identification of a novel C616Y point mutation in a PV patient
S. -J Zhang et al.
INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY (2007)
JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis
Linda M. Scott et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
JAK2 V617F due to a novel TG -> CT mutation at nucleotides 1848-1849: diagnostic implication
C. L. P. Wong et al.
LEUKEMIA (2007)
Bone marrow JAK2V617F allele burden and clinical correlates in polycythemia vera
A. Tefferi et al.
LEUKEMIA (2007)
Polycythemia vera is not initiated by JAK2(V17F) mutation
Roberto H. Nussenzveig et al.
EXPERIMENTAL HEMATOLOGY (2007)
EXEL-0862, a novel tyrosine kinase inhibitor, induces apoptosis in vitro and ex vivo in human mast cells expressing the KIT D816V mutation
Jingxuan Pan et al.
BLOOD (2007)
Evidence that the JAK2 G1849T (V617F) mutation occurs in a lymphomyeloid progenitor in polycythemia vera and idiopathic myelofibrosis
Francois Delhommeau et al.
BLOOD (2007)
Sensitive and reliable detection of Kit point mutation Asp 816 to Val in pathological material
Christian Kaehler et al.
DIAGNOSTIC PATHOLOGY (2007)
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
Brian J. Druker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Report on two novel nucleotide exchanges in the JAK2 pseudokinase domain:: D620E and E627E
S. Schnittger et al.
LEUKEMIA (2006)
Concurrent MPL515 and JAK2V617F mutations in myelofibrosis:: chronology of clonal emergence and changes in mutant allele burden over time
Terra L. Lasho et al.
BRITISH JOURNAL OF HAEMATOLOGY (2006)
Detection of a new JAK2 D620E mutation in addition to V617F in a patient with polycythemia vera
F. Gruenebach et al.
LEUKEMIA (2006)
MPL515 mutations in myeloproliferative and other myeloid disorders:: a study of 1182 patients
Animesh D. Pardanani et al.
BLOOD (2006)
Mutation of JAK2 in the myeloproliferative disorders:: timing, clonality studies, cytogenetic associations, and role in leukemic transformation
Peter J. Campbell et al.
BLOOD (2006)
Expression of TEL-JAK2 in primary human hematopoietic cells drives erythropoietin-independent erythropoiesis and induces myelofibrosis in vivo
J. A. Kennedy et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
JAK2V617F mutational frequency in polycythemia vera:: 100%, > 90%, less?
S. Verstovsek et al.
LEUKEMIA (2006)
Effects of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, on human mast cells bearing wild-type or mutated codon 816 c-kit
Srdan Verstovsek et al.
LEUKEMIA RESEARCH (2006)
High occurrence of JAK2 V617 mutation in refractory anemia with ringed sideroblasts associated with marked thrombocytosis
A. Renneville et al.
LEUKEMIA (2006)
Involvement of various hematopoietic-cell lineages by the JAK2V617F mutation in polycythemia vera
Takefumi Ishii et al.
BLOOD (2006)
JAK2T875N is a novel activating mutation that results in myeloproliferative disease with features of megakaryoblastic leukemia in a murine bone marrow transplantation model
Thomas Mercher et al.
BLOOD (2006)
Transient response to imatinib in a chronic eosinophilic leukemia associated with ins(9;4)(q33;q12q25) and a CDK5RA4P2-PDGFRA fusion gene
Christoph Walz et al.
GENES CHROMOSOMES & CANCER (2006)
Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia
Linda M. Scott et al.
BLOOD (2006)
KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders:: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients
Andres C. Garcia-Montero et al.
BLOOD (2006)
The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera
Eric Lippert et al.
BLOOD (2006)
Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet
Michele Baccarani et al.
BLOOD (2006)
Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders
Robert Kralovics et al.
BLOOD (2006)
Sorafenib is a potent inhibitor of HP1L1-PDGFRα and the imatinib-resistant FIP1L1-PDGFRα T674I mutant
Els Lierman et al.
BLOOD (2006)
Rapamycin inhibits growth and survival of D816V-mutated c-kit mast cells
Marion Gabillot-Carre et al.
BLOOD (2006)
Imatinib mesylate in the treatment of systemic mastocytosis - A phase II trial
Helga J. Droogendijk et al.
CANCER (2006)
Activating alleles of JAK3 in acute megakaryoblastic leukemia
Denise K. Walters et al.
CANCER CELL (2006)
Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis
Neil P. Shah et al.
BLOOD (2006)
MPLW515L is anovel somatic activating mutation in myelofibrosis with myeloid metaplasia
Yana Pikman et al.
PLOS MEDICINE (2006)
Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disorders
Christine Bellanne-Chantelot et al.
BLOOD (2006)
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias
Moshe Talpaz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
The FIP1L1-PDGFRA T674I mutation can be inhibited by the tyrosine kinase inhibitor AMN107 (nilotinib)
Nikolas von Bubnoff et al.
BLOOD (2006)
Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL
Hagop Kantarjian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Activity of dual SRC-ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistance
Mohammad Azam et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome
Raj K. Patel et al.
GASTROENTEROLOGY (2006)
Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model
Gerlinde Wernig et al.
BLOOD (2006)
JAK2 V617F is a rare finding in de novo acute myeloid leukemia, but STAT3 activation is common and remains unexplained
D. P. Steensma et al.
LEUKEMIA (2006)
Activation of FIP1L1-PDGFRα requires disruption of the juxtamembrane domain of PDGFRα and is FIP1L1-independent
Elizabeth H. Stover et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Mechanisms of disease: Lineage-specific hematopoietic growth factors
K Kaushansky
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Identification of a novel imatinib responsive KIF5B-PDGFRA fusion gene following screening for PDGFRA overexpression in patients with hypereosinophilia
J Score et al.
LEUKEMIA (2006)
The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation
CHM Jamieson et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
The JAK2 V617F mutation in de novo acute myelogenous leukemias
JW Lee et al.
ONCOGENE (2006)
JAK2 V617F mutation in classic chronic myeloproliferative diseases:: a report on a series of 349 patients
JL Vizmanos et al.
LEUKEMIA (2006)
Absence of JAK2 V617F mutation in gastric cancers
JW Lee et al.
ACTA ONCOLOGICA (2006)
V617F mutation in JAK2 is associated idiopathic myelofibrosis
PJ Campbell et al.
BLOOD (2006)
A t(8;9) translocation with PCM1-JAK2 fusion in a patient with T-cell lymphoma
J Adélaïde et al.
LEUKEMIA (2006)
The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera
A Tefferi et al.
CANCER (2006)
Multilineage involvement of the fusion gene in patients with FIP1L1/PDGFRA-positive hypereosinophilic syndrome
J Robyn et al.
BRITISH JOURNAL OF HAEMATOLOGY (2006)
JAK2 V617F mutation is uncommon in non-Hodgkin lymphomas
JW Lee et al.
LEUKEMIA & LYMPHOMA (2006)
Mutational screen reveals a novel JAK2 mutation, L611S, in a child with acute lymphoblastic leukemia
CP Kratz et al.
LEUKEMIA (2006)
PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT:: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects
KV Gleixner et al.
BLOOD (2006)
Absence of the JAK2 V617F activating mutation in classical Hodgkin lymphoma and primary mediastinal B-cell lymphoma
I Melzner et al.
LEUKEMIA (2006)
A transgenic mouse model for TEL-JAK2-induced B-cell lymphoma/leukemia
NR dos Santos et al.
LEUKEMIA (2006)
Chronic eosinophilic leukaemia with FIP1L1-PDGFRA fusion and T674I mutation that evolved from Langerhans cell histiocytosis with eosinophilia after chemotherapy
Hiroaki Ohnishi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2006)
Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT Isoforms associated with human malignancies
MM Schittenhelm et al.
CANCER RESEARCH (2006)
JAK2(V617F) expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis
Catherine Lacout et al.
BLOOD (2006)
Anticipating clinical resistance to target-directed agents - The BCR-ABL paradigm
Mohammad Azam et al.
MOLECULAR DIAGNOSIS & THERAPY (2006)
Mastocytosis in mice expressing human Kit receptor with the activating Asp816Val mutation
JP Zappulla et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status:: a prospective study
PJ Campbell et al.
LANCET (2005)
Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2
R Kralovics et al.
BLOOD (2005)
The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia
RL Levine et al.
BLOOD (2005)
The t(8;9)(p22;p24) translocation in atypical chronic myeloid leukaemia yields a new PCM1-JAK2 fusion gene
M Bousquet et al.
ONCOGENE (2005)
The JAK2V617F tyrosine kinase mutation in myelofibrosis with myeloid metaplasia:: lineage specificity and clinical correlates
A Tefferi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFRβ and FIP1L1-PDGFRα in vitro and in vivo
EH Stover et al.
BLOOD (2005)
A BCR-JAK2 fusion gene as the result of a t(9;22)(p24;q 11.2) translocation in a patient with a clinically typical chronic myeloid leukemia
F Griesinger et al.
GENES CHROMOSOMES & CANCER (2005)
The V617F JAK2 mutation is uncommon in cancers and in myeloid malignancies other than the classic myeloproliferative disorders
LM Scott et al.
BLOOD (2005)
Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation
J Gotlib et al.
BLOOD (2005)
JAK2V617F mutation in essential thrombocythaemia:: clinical associations and long-term prognostic relevance
AP Wolanskyj et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
Concomitant neutrophil JAK2V617F mutation screening and PRV-1 expression analysis in myeloproliferative disorders and secondary polycythaemia
A Tefferi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
Clinical implications of the JAK2 V617F mutation in essential thrombocythemia
E Antonioli et al.
LEUKEMIA (2005)
Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders
AV Jones et al.
BLOOD (2005)
The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both atypical myeloproliferative disorders and myelodysplastic syndromes
DP Steensma et al.
BLOOD (2005)
Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases
TA Carter et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Activation mutations of human c-KIT resistant to imatinib, mesylate are sensitive to the tyrosine kinase inhibitor PKC412
JD Growney et al.
BLOOD (2005)
Enabling death by the Abl tyrosine kinase - Mechanisms for nuclear shuttling of c-Abl in response to DNA damage
K Yoshida et al.
CELL CYCLE (2005)
c-kit mutations in patients with childhood-onset mastocytosis and genotype-phenotype correlation
H Yanagihori et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2005)
Molecular characterization of the idiopathic hypereosinophilic syndrome (HES) in 35 French patients with normal conventional cytogenetics
C Roche-Lestienne et al.
LEUKEMIA (2005)
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
C James et al.
NATURE (2005)
A gain-of-function mutation of JAK2 in myeloproliferative disorders
R Kralovics et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Insights into selective activation of p53 DNA binding by c-abl
G Wei et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2
A Reiter et al.
CANCER RESEARCH (2005)
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
RL Levine et al.
CANCER CELL (2005)
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
EJ Baxter et al.
LANCET (2005)
A novel NF-κB inhibitor, IMD-0354, suppresses neoplastic proliferation of human mast cells with constitutively activated c-kit receptors
A Tanaka et al.
BLOOD (2005)
8pII myeloproliferative syndrome with a novel t(7;8) translocation leading to fusion of the FGFRI and TIFI genes
E Belloni et al.
GENES CHROMOSOMES & CANCER (2005)
Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia
R Ren
NATURE REVIEWS CANCER (2005)
PKCδ plays opposite roles in growth mediated by wild-type Kit and an oncogenic Kit mutant
T Jelacic et al.
BLOOD (2005)
Myeloid blast crisis evolving during imatinib treatment of an FIP1L1-PDGFR alpha-positive chronic myeloproliferative disease with prominent eosinophilia
N von Bubnoff et al.
LEUKEMIA (2005)
KIT (CD117): A review on expression in normal and neoplastic tissues, and mutations and their clinicopathologic correlation
M Miettinen et al.
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY (2005)
The systemic mastocytosis-specific activating cKit mutation D816V can be inhibited by the tyrosine kinase inhibitor AMN107
N von Bubnoff et al.
LEUKEMIA (2005)
PCM1-JAK2 fusion in myeloproliferative disorders and acute erythroid leukemia with t(8;9) translocation
A Murati et al.
LEUKEMIA (2005)
The V617F mutation in Jak2 is not found in childhood acute lymphoblastic leukaemia
S Sulong et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
Mutation studies in CD3(+), CD19(+) and CD34(+) cell fractions in myeloproliferative disorders with homozygous JAK2(V617F) in granulocytes
TL Lasho et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
Identification of a novel gene, FGFR1OP2, fused to FGFR1 in 8p11 myeloproliferative syndrome
EK Grand et al.
GENES CHROMOSOMES & CANCER (2004)
NIN, a gene encoding a CEP110-like centrosomal protein, is fused to PDGFRB in a patient with a t(5;14)(q33;q24) and an imatinib-responsive myeloproliferative disorder
JL Vizmanos et al.
CANCER RESEARCH (2004)
HCMOGT-1 is a novel fusion partner to PDGFRB in juvenile myelomonocytic leukemia with t(5;17)(q33;p11.2)
C Morerio et al.
CANCER RESEARCH (2004)
A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib
C Akin et al.
BLOOD (2004)
Distinct stem cell myeloproliferative/T lymphoma syndromes induced by ZNF198-FGFR1 and BCR-FGFR1 fusion genes from 8p11 translocations
S Roumiantsev et al.
CANCER CELL (2004)
JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis
LS Steelman et al.
LEUKEMIA (2004)
Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome
AD Klion et al.
BLOOD (2004)
Mpl Baltimore: A thrombopoietin receptor polymorphism associated with thrombocytosis
AR Moliterno et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Overriding imatinib resistance with a novel ABL kinase inhibitor
NP Shah et al.
SCIENCE (2004)
FIP1L1-PDGFRA fusion:: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia
A Pardanani et al.
BLOOD (2004)
Demonstration that mast cells, T cells, and B cells bearing the activating kit mutation D816V occur in clusters within the marrow of patients with mastocytosis
ML Taylor et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2004)
FOP-FGFR1 tyrosine kinase, the product of a t(6;8) translocation, induces a fatal myeloproliferative disease in mice
G Guasch et al.
BLOOD (2004)
p53-binding protein 1 is fused to the platelet-derived growth factor receptor β in a patient with a t(5;15)(q33;q22) and an imatinib-responsive eosinophilic myeloproliferative disorder
FH Grand et al.
CANCER RESEARCH (2004)
Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin
F Ding et al.
BLOOD (2004)
PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder
J Chen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Signal transduction via the stem cell factor receptor/c-Kit
L Rönnstrand
CELLULAR AND MOLECULAR LIFE SCIENCES (2004)
How do Abl family kinases regulate cell shape and movement?
SE Hernandez et al.
TRENDS IN CELL BIOLOGY (2004)
Mechanisms of transformation by the BCR-ABL oncogene:: new perspectives in the post-imatinib era
RA Van Etten
LEUKEMIA RESEARCH (2004)
Molecular and cytogenetic characterization of a novel translocation t(4;22) involving the breakpoint cluster region and platelet-derived growth factor receptor-alpha genes in a patient with atypical chronic myeloid leukemia
AM Safley et al.
GENES CHROMOSOMES & CANCER (2004)
Chronic myeloproliferative disorders with rearrangement of the platelet-derived growth factor α receptor:: a new clinical target for STI571/Glivec
P Trempat et al.
ONCOGENE (2003)
Imatinib for systemic mast-cell disease
A Pardanani et al.
LANCET (2003)
Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit
C Akin et al.
EXPERIMENTAL HEMATOLOGY (2003)
Clinical and genetic studies of ETV6/ABL1-positive chronic myeloid leukaemia in blast crisis treated with imatinib mesylate
A Barbouti et al.
BRITISH JOURNAL OF HAEMATOLOGY (2003)
Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome
JH Griffin et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Constitutively active mutant D816VKit induces megakayocyte and mast cell differentiation of early haemopoietic cells from murine foetal liver
PT Ferrao et al.
LEUKEMIA RESEARCH (2003)
Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders
A Pardanani et al.
BLOOD (2003)
PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRα-induced myeloproliferative disease
J Cools et al.
CANCER CELL (2003)
A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome
J Cools et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-kit receptors found in mast cell neoplasms
Y Zermati et al.
ONCOGENE (2003)
Endogenous retroviral sequence is fused to FGFR1 kinase in the 8p12 stem-cell myeloproliferative disorder with t(8;19)(p12;q13.3)
G Guasch et al.
BLOOD (2003)
Cloning of the t(l;5)(q23;q33) in a myeloproliferative disorder associated with eosinophilia: involvement of PDGFRB and response to imatinib
K Wilkinson et al.
BLOOD (2003)
CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy
A Pardanani et al.
BLOOD (2003)
Identification of an ETV6-ABL2 fusion transcript in combination with an ETV6 point mutation in a T-cell acute lymphoblastic leukaemia cell line
F Griesinger et al.
BRITISH JOURNAL OF HAEMATOLOGY (2002)
Chronic myelocytic leukemia with eosinophilia, t(9;12)(q34;p13), and ETV6-ABL gene rearrangement: case report and review of the literature
YK Keung et al.
CANCER GENETICS AND CYTOGENETICS (2002)
A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias
OG Ottmann et al.
BLOOD (2002)
Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta
JF Apperley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
GD Demetri et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Evidence for the involvement of a hematopoietic progenitor cell in systemic mastocytosis from single-cell analysis of mutations in the c-kit gene
AS Yavuz et al.
BLOOD (2002)
The Tel-Abl (ETV6-Abl) tyrosine kinase, product of complex (9;12) translocations in human leukemia, induces distinct myeloproliferative disease in mice
RP Million et al.
BLOOD (2002)
The t(4;22)(q12;q11) in atypical chronic myeloid leukaemia fuses BCR to PDGFRA
EJ Baxter et al.
HUMAN MOLECULAR GENETICS (2002)
Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study
CL Sawyers et al.
BLOOD (2002)
Imatinib mesylate (ST1571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase
HM Kantarjian et al.
BLOOD (2002)
Treatment of hypereosinophilic syndrome with imatinib mesilate
GJ Gleich et al.
LANCET (2002)
Transient response to imatinib mesylate (STI571) in a patient with the ETV6-ABL t(9;12) translocation
SG O'Brien et al.
BLOOD (2002)
Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study
M Talpaz et al.
BLOOD (2002)
Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia.
H Kantarjian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
The t(8;22) in chronic myeloid leukemia fuses BCR to FGFR1: transforming activity and specific inhibition of FGFR1 fusion proteins
A Demiroglu et al.
BLOOD (2001)
8p12 stem cell myeloproliferative disorder:: the FOP-fibroblast growth factor receptor 1 fusion protein of the t(6;8) translocation induces cell survival mediated by mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt/mTOR pathways
G Guasch et al.
MOLECULAR AND CELLULAR BIOLOGY (2001)
Fusion of the BCR and the fibroblast growth factor receptor-1 (FGFR1) genes as a result of t(8;22)(p11;q11) in a myeloproliferative disorder:: The first fusion gene involving BCR but not ABL
T Fioretos et al.
GENES CHROMOSOMES & CANCER (2001)
Safety and efficacy of imatinib (ST1571) in metastatic gastrointestinal stromal tumours: a phase I study
AT van Oosterom et al.
LANCET (2001)
Rabaptin-5 is a novel fusion partner to platelet-derived growth factor β receptor in chronic myelomonocytic leukemia
MK Magnusson et al.
BLOOD (2001)
Identification of four new translocations involving FGFRI in myeloid disorders
J Sohal et al.
GENES CHROMOSOMES & CANCER (2001)
The Kit-activating mutation D816V enhances stem cell factor-dependent chemotaxis
ML Taylor et al.
BLOOD (2001)
H4(D10S170), a gene frequently rearranged in papillary thyroid carcinoma, is fused to the platelet-derived growth factor receptor β gene in atypical chronic myeloid leukemia with t(5;10)(q33;q22)
J Schwaller et al.
BLOOD (2001)
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.
BJ Druker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the philadelphia chromosome.
BJ Druker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
c-mpl mutations are the cause of congenital amegakaryocytic thrombocytopenia
M Ballmaier et al.
BLOOD (2001)
The 8p12 myeloproliferative disorder. t(8;19)(p12;q13.3):: a novel translocation involving the FGFR1 gene
F Mugneret et al.
BRITISH JOURNAL OF HAEMATOLOGY (2000)
Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase
T Schindler et al.
SCIENCE (2000)
Analysis of the surface expression of c-kit and occurrence of the c-kit Asp816Val activating mutation in T cells, B cells, and myelomonocytic cells in patients with mastocytosis
C Akin et al.
EXPERIMENTAL HEMATOLOGY (2000)
分享论文
